Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts | Synapse
December 26, 2023Open Access
Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts
Key Points
Key points are not available for this paper at this time.
Abstract
The findings of this study provide robust real-world evidence to support the broad use of B/F/TAF in both TN and TE people with HIV.